EA201101668A1 - Редокс-активные терапевтические средства для лечения митохондриальных нарушений - Google Patents
Редокс-активные терапевтические средства для лечения митохондриальных нарушенийInfo
- Publication number
- EA201101668A1 EA201101668A1 EA201101668A EA201101668A EA201101668A1 EA 201101668 A1 EA201101668 A1 EA 201101668A1 EA 201101668 A EA201101668 A EA 201101668A EA 201101668 A EA201101668 A EA 201101668A EA 201101668 A1 EA201101668 A1 EA 201101668A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- redox
- treatment
- active therapeutic
- therapeutic means
- mitochondrial disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/06—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by conversion of non-aromatic six-membered rings or of such rings formed in situ into aromatic six-membered rings, e.g. by dehydrogenation
- C07C37/07—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by conversion of non-aromatic six-membered rings or of such rings formed in situ into aromatic six-membered rings, e.g. by dehydrogenation with simultaneous reduction of C=O group in that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
- C07C39/08—Dihydroxy benzenes; Alkylated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/18—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring
- C07C39/19—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/245—Halogenated derivatives monocyclic polyhydroxylic containing halogens bound to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
- C07C46/02—Preparation of quinones by oxidation giving rise to quinoid structures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
- C07C46/02—Preparation of quinones by oxidation giving rise to quinoid structures
- C07C46/06—Preparation of quinones by oxidation giving rise to quinoid structures of at least one hydroxy group on a six-membered aromatic ring
- C07C46/08—Preparation of quinones by oxidation giving rise to quinoid structures of at least one hydroxy group on a six-membered aromatic ring with molecular oxygen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/02—Quinones with monocyclic quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/02—Quinones with monocyclic quinoid structure
- C07C50/06—Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Раскрываются способы лечения или супрессии митохондриальных заболеваний, таких как атаксия Фридрейха (FRDA), наследственная оптическая невропатия Лебера (LHON), митохондриальная миопатия, энцефалопатия, молочнокислый ацидоз, инсульт (MELAS) или синдром Кернса-Сейра (KSS), а также соединения, применимые в способах изобретения, такие как хинон альфа-токоферола.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68682605P | 2005-06-01 | 2005-06-01 | |
US70181505P | 2005-07-21 | 2005-07-21 | |
US77602806P | 2006-02-22 | 2006-02-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201101668A1 true EA201101668A1 (ru) | 2012-05-30 |
EA035619B1 EA035619B1 (ru) | 2020-07-16 |
Family
ID=37307328
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201101668A EA035619B1 (ru) | 2005-06-01 | 2006-06-01 | Композиции для использования в способе лечения митохондриальных нарушений |
EA200702622A EA016226B1 (ru) | 2005-06-01 | 2006-06-01 | Редокс-активные терапевтические соединения для лечения митохондриальных заболеваний |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200702622A EA016226B1 (ru) | 2005-06-01 | 2006-06-01 | Редокс-активные терапевтические соединения для лечения митохондриальных заболеваний |
Country Status (14)
Country | Link |
---|---|
US (3) | US9447006B2 (ru) |
EP (4) | EP1888059B1 (ru) |
JP (6) | JP2008542389A (ru) |
CA (2) | CA2996149A1 (ru) |
DK (3) | DK1888059T3 (ru) |
EA (2) | EA035619B1 (ru) |
ES (3) | ES2714900T3 (ru) |
HK (1) | HK1108651A1 (ru) |
HU (1) | HUE033304T2 (ru) |
MX (3) | MX359292B (ru) |
PL (3) | PL1888059T3 (ru) |
PT (2) | PT1888059E (ru) |
SI (1) | SI1888059T1 (ru) |
WO (1) | WO2006130775A2 (ru) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2580584C (en) | 2003-09-19 | 2015-07-28 | Galileo Pharmaceuticals, Inc. | Use of alpha-tocotrienol for treatment of mitochondrial diseases |
ES2714900T3 (es) | 2005-06-01 | 2019-05-30 | Bioelectron Tech Corp | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
US9050005B2 (en) | 2005-08-25 | 2015-06-09 | Synapse Biomedical, Inc. | Method and apparatus for transgastric neurostimulation |
WO2007035496A1 (en) * | 2005-09-15 | 2007-03-29 | Edison Pharmaceuticals, Inc. | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
EP2617418B1 (en) * | 2006-02-22 | 2017-11-22 | BioElectron Technology Corporation | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
US8676323B2 (en) | 2006-03-09 | 2014-03-18 | Synapse Biomedical, Inc. | Ventilatory assist system and methods to improve respiratory function |
US20080097153A1 (en) * | 2006-08-24 | 2008-04-24 | Ignagni Anthony R | Method and apparatus for grasping an abdominal wall |
WO2008098001A2 (en) | 2007-02-05 | 2008-08-14 | Synapse Biomedical, Inc. | Removable intramuscular electrode |
WO2008144578A1 (en) | 2007-05-17 | 2008-11-27 | Synapse Biomedical, Inc. | Devices and methods for assessing motor point electromyogram as a biomarker |
WO2009059033A1 (en) | 2007-10-30 | 2009-05-07 | Synapse Biomedical, Inc. | Method of improving sleep disordered breathing |
US8428726B2 (en) | 2007-10-30 | 2013-04-23 | Synapse Biomedical, Inc. | Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system |
EP3456707B1 (en) | 2007-11-06 | 2020-04-15 | PTC Therapeutics, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
US8952071B2 (en) * | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
US20110046156A1 (en) | 2008-03-05 | 2011-02-24 | Miller Guy M | Treatment of hearing and balance impairments with redox-active therapeutics |
JP5710277B2 (ja) * | 2008-03-05 | 2015-04-30 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス疾患の処置のための2−置換−p−キノン誘導体 |
US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
US8314153B2 (en) | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
DK2362875T3 (en) | 2008-10-28 | 2015-11-30 | Edison Pharmaceuticals Inc | METHOD OF PRODUCING ALPHA-tocotrienol AND DERIVATIVES |
HUE037574T2 (hu) * | 2009-04-28 | 2018-09-28 | Bioelectron Tech Corp | Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal |
US20100273892A1 (en) * | 2009-04-28 | 2010-10-28 | Miller Guy M | Formulations of tocotrienol quinones for the treatment of ophthalmic diseases |
CN102647981B (zh) * | 2009-08-26 | 2016-09-28 | 爱迪生制药有限公司 | 预防和治疗脑缺血的方法 |
WO2011051357A1 (en) * | 2009-10-27 | 2011-05-05 | Loeffler Bernd-Michael | Therapeutic gas for the treatment of mitochondrial disorders |
US20110172312A1 (en) * | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
US20110263720A1 (en) * | 2010-03-09 | 2011-10-27 | Penwest Pharmaceuticals Co. | Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
EA201201374A1 (ru) * | 2010-04-06 | 2013-04-30 | Эдисон Фармасьютикалз, Инк. | Лечение атаксии-телеангиэктазии |
MY183449A (en) * | 2010-04-27 | 2021-02-18 | Bioelectron Tech Corp | Formulations of quinones for the treatment of ophthalmic diseases |
WO2012019032A1 (en) * | 2010-08-06 | 2012-02-09 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
JP6045494B2 (ja) * | 2010-08-06 | 2016-12-14 | エジソン ファーマシューティカルズ, インコーポレイテッド | ナフトキノンによるミトコンドリア病の処置 |
EP2606022A2 (en) | 2010-08-16 | 2013-06-26 | Santhera Pharmaceuticals (Schweiz) AG | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
WO2012022468A2 (en) | 2010-08-16 | 2012-02-23 | Santhera Pharmaceuticals (Schweiz) Ag | Benzoquinone derivatives as modulators of mitchondrial function |
WO2012068552A1 (en) * | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
WO2012136680A1 (en) * | 2011-04-07 | 2012-10-11 | Akzo Nobel Chemicals International B.V. | Process for the production of dialkyl zinc and dialkyl aluminium halide |
WO2012174286A1 (en) * | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
US20150057363A1 (en) * | 2011-07-06 | 2015-02-26 | Guy M. Miller | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
US9162957B2 (en) | 2011-07-19 | 2015-10-20 | Edison Pharmaceuticals, Inc. | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
EP2573063A1 (en) | 2011-09-23 | 2013-03-27 | DSM IP Assets B.V. | Process for preparing chiral quinone |
US9629815B2 (en) | 2012-09-07 | 2017-04-25 | Bioelectron Technology Corporation | Benzoquinone derivatives for treating oxidative stress disorders |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
EP2970158B1 (en) | 2013-03-15 | 2019-02-20 | BioElectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
EP3004071A1 (en) | 2013-05-31 | 2016-04-13 | Edison Pharmaceuticals, Inc. | Carboxylic acid derivatives for treatment of oxidative stress disorders |
CN104387253A (zh) * | 2014-11-03 | 2015-03-04 | 南昌大学 | α–生育醌在治疗糖尿病或肥胖症药物中的应用 |
JP2018500317A (ja) | 2014-12-16 | 2018-01-11 | バイオエレクトロン テクノロジー コーポレイション | トロロックスのキラル分割のための方法 |
RU2770091C2 (ru) | 2014-12-16 | 2022-04-14 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида |
JP2018502127A (ja) | 2015-01-12 | 2018-01-25 | バイオエレクトロン テクノロジー コーポレイション | 放射線被曝に対する防護のためのキノン |
EP3359521A1 (en) * | 2015-10-08 | 2018-08-15 | Khondrion Ip B.V. | Novel compounds for treating mitochondrial disease |
US10745371B2 (en) | 2015-12-16 | 2020-08-18 | Ptc Therapeutics, Inc. | Methods for enriching alpha-tocotrienol from mixed tocol compositions |
US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
WO2017123822A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
WO2018129411A1 (en) | 2017-01-06 | 2018-07-12 | Bioelectron Technology Corporation | Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders |
CA3097114A1 (en) | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
CN113365616A (zh) | 2018-10-17 | 2021-09-07 | Ptc医疗公司 | 用于抑制和治疗α-突触核蛋白病、tau蛋白病及其他疾病的2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮 |
CN109704938B (zh) * | 2018-12-19 | 2022-02-22 | 江南大学 | 一种生育酚单体制备对醌的方法 |
US11471683B2 (en) | 2019-01-29 | 2022-10-18 | Synapse Biomedical, Inc. | Systems and methods for treating sleep apnea using neuromodulation |
CA3156499A1 (en) | 2019-10-04 | 2021-04-08 | Stealth Biotherapeutics Inc. | CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS |
WO2021077034A1 (en) | 2019-10-18 | 2021-04-22 | Ptc Therapeutics, Inc. | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders |
EP4351547A1 (en) * | 2021-06-10 | 2024-04-17 | Stealth BioTherapeutics Inc. | Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia |
KR20240032997A (ko) | 2021-07-08 | 2024-03-12 | 피티씨 테라퓨틱스, 인크. | 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온을 포함하는 약제학적 조성물 |
Family Cites Families (239)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2856414A (en) | 1958-10-14 | Oxidation of alpha-tocopherol | ||
US2398418A (en) | 1943-08-27 | 1946-04-16 | Louis F Fieser | Introduction of organic radicals into quinones |
FR1201200A (fr) | 1958-08-08 | 1959-12-29 | Sogespar S A | Procédé de fabrication de l'alpha tocophéryl-quinone |
US3071512A (en) | 1959-01-26 | 1963-01-01 | Sogespar S A | New hypotensive pharmaceutical preparation containing alpha-tocopheryl-quinone |
US3406188A (en) | 1964-03-27 | 1968-10-15 | Sun Oil Co | Preparation of alpha-tocopherylquinone |
FR5531M (ru) | 1966-02-08 | 1967-11-13 | ||
FR1536576A (fr) | 1967-08-29 | 1968-08-16 | Eastman Kodak Co | Procédés d'enrichissement et de fractionnement de mélanges à base de tocophérols |
US3728363A (en) | 1970-03-17 | 1973-04-17 | Takeda Chemical Industries Ltd | Quinone derivatives |
US3705239A (en) | 1970-10-16 | 1972-12-05 | Roy B Gregory | Pain removing compositions and methods |
UST917001I4 (en) | 1971-12-02 | 1973-12-04 | Defensive publication | |
JPS4875564U (ru) | 1971-12-21 | 1973-09-19 | ||
JPS4875564A (ru) | 1972-01-08 | 1973-10-11 | ||
JPS4988862U (ru) | 1972-11-20 | 1974-08-01 | ||
JPS4988862A (ru) | 1972-12-29 | 1974-08-24 | ||
JPS5245698B2 (ru) | 1973-04-06 | 1977-11-17 | ||
DE2431198A1 (de) | 1973-07-02 | 1975-01-23 | Takeda Chemical Industries Ltd | Chinonderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittelzubereitungen |
US3909376A (en) | 1974-12-04 | 1975-09-30 | Basf Ag | Electrolytic manufacture of alkyl-substituted hydroquinones |
US3939376A (en) * | 1974-12-26 | 1976-02-17 | Union Carbide Corporation | Alignment spring counteracting antenna type getter effect on electron gun alignment |
JPS52111576A (en) | 1976-03-15 | 1977-09-19 | Teijin Ltd | Synthesis of 5,7,8-trimethyl-3,4-dehydrotocotrienol |
JPS52130922U (ru) | 1976-03-31 | 1977-10-05 | ||
JPS5938203B2 (ja) | 1976-04-26 | 1984-09-14 | エーザイ株式会社 | 補酵素qを主成分とする脳循環障害治療剤 |
US4153614A (en) | 1978-05-12 | 1979-05-08 | Hoffmann-La Roche Inc. | Synthesis of (S)-(+)-6-hydroxy-2,5,7,8-tetramethylchroman-2-methanol and intermediates therein |
LU77344A1 (ru) | 1977-05-16 | 1979-01-19 | ||
US4201879A (en) | 1977-05-16 | 1980-05-06 | Hoffmann-La Roche Inc. | Hydroquinones |
US4201726A (en) | 1977-05-17 | 1980-05-06 | Hoffmann-La Roche Inc. | Synthesis of Vitamin E |
US4243598A (en) | 1977-05-17 | 1981-01-06 | Hoffmann-La Roche Inc. | Synthesis of vitamin E |
US4185154A (en) | 1977-05-17 | 1980-01-22 | Hoffmann-La Roche, Inc. | Synthesis of vitamin E |
US4127608A (en) | 1977-05-17 | 1978-11-28 | Hoffmann-La Roche Inc. | Synthesis of Vitamin E |
US4310465A (en) | 1977-05-17 | 1982-01-12 | Hoffmann-La Roche Inc. | Synthesis of vitamin E and quinone intermediates |
JPS5818374Y2 (ja) | 1978-07-29 | 1983-04-14 | 日本電気ホームエレクトロニクス株式会社 | 複合テレビジヨン受像機のキヤビネツト |
JPS5640651A (en) | 1979-09-12 | 1981-04-16 | Takeda Chem Ind Ltd | Quinone compound and its preparation |
JPS567734A (en) | 1979-06-28 | 1981-01-27 | Takeda Chem Ind Ltd | Preparation of quinone derivative |
JPS56147746A (en) | 1980-04-15 | 1981-11-16 | Takeda Chem Ind Ltd | Quinones and their preparation |
JPS567737A (en) | 1979-07-02 | 1981-01-27 | Takeda Chem Ind Ltd | Physiologically active quinone and its preparation |
JPS5697223A (en) | 1979-12-30 | 1981-08-05 | Takeda Chem Ind Ltd | Tissue metabolism activator |
JPH0193554A (ja) | 1980-04-07 | 1989-04-12 | Takeda Chem Ind Ltd | 有機化合物 |
JPS56140943A (en) | 1980-04-07 | 1981-11-04 | Takeda Chem Ind Ltd | Preparation of organic compound |
US4393075A (en) | 1980-04-14 | 1983-07-12 | Takeda Chemical Industries, Ltd. | Quinone compounds and their use in suppressing the production of SRS-A in mammals |
JPS5750935A (en) | 1980-09-12 | 1982-03-25 | Otsuka Pharmaceut Co Ltd | 1,4-benzoquinone derivative |
JPS57131735A (en) | 1981-02-09 | 1982-08-14 | Takeda Chem Ind Ltd | Preparation of quinones |
JPS57183782A (en) | 1981-04-30 | 1982-11-12 | Sumitomo Chem Co Ltd | Preparation of coumarone compound |
JPS5818374A (ja) | 1981-07-27 | 1983-02-02 | Nitsusui Seiyaku Kk | エイコサペンタエン酸トコフエロ−ルエステル |
JPS5883698A (ja) | 1981-11-13 | 1983-05-19 | Takeda Chem Ind Ltd | キノン化合物およびその製造法 |
JPS58193689A (ja) | 1982-05-10 | 1983-11-11 | Shiseido Co Ltd | テストステロン−5α−レダクタ−ゼ阻害剤 |
DK449983A (da) | 1982-10-27 | 1984-04-28 | Hoffmann La Roche | Fremgangsmaade til fremstilling af optiske aktive forbindelser |
CH655005A5 (it) | 1983-02-16 | 1986-03-27 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare. |
JPS59163316A (ja) | 1983-03-08 | 1984-09-14 | Eisai Co Ltd | けいれんの治療・予防剤 |
JPS6028919A (ja) | 1983-07-28 | 1985-02-14 | Shiseido Co Ltd | 皮膚外用剤 |
EP0134198A1 (de) | 1983-08-10 | 1985-03-13 | Ciba-Geigy Ag | Verwendung von Chinonderivaten zum Schützen von Kulturpflanzen vor der phytotoxischen Wirkung von Herbiziden |
JPS60197621A (ja) | 1984-03-19 | 1985-10-07 | Hohnen Oil Co Ltd | コレステロ−ル低下剤 |
US5304658A (en) | 1984-08-01 | 1994-04-19 | Takeda Chemical Industries, Ltd. | Quinone derivatives, their production and use |
MX9203040A (es) | 1984-08-01 | 1992-07-31 | Takeda Chemical Industries Ltd | Derivados de quinona y composicion farmaceutica que los contiene. |
JPS6140236A (ja) | 1984-08-02 | 1986-02-26 | Yamanouchi Pharmaceut Co Ltd | ハイドロキノン誘導体 |
US4592867A (en) | 1984-10-19 | 1986-06-03 | Energy Conversion Devices, Inc. | Synthesis method for reductant precursor |
US4617317A (en) | 1984-10-31 | 1986-10-14 | Bennet Justin D | Method of treating ulcerative colitis |
EP0183869B1 (en) | 1984-12-06 | 1991-04-17 | Kuraray Co., Ltd. | Chroman compounds and their use |
US5229385A (en) | 1986-01-30 | 1993-07-20 | Takeda Chemical Industries, Ltd. | Quinone derivatives, their production and use |
US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
JPH0788376B2 (ja) | 1986-09-02 | 1995-09-27 | エーザイ株式会社 | 光学活性α−トコトリエノ−ルの製造方法 |
JPH0445016Y2 (ru) | 1986-10-17 | 1992-10-22 | ||
GB8626344D0 (en) | 1986-11-04 | 1986-12-03 | Zyma Sa | Bicyclic compounds |
US5057514A (en) | 1987-02-03 | 1991-10-15 | Suntory Limited | Compounds effective as cerebral schemia treating agents |
US4914088A (en) | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
US5292768A (en) | 1987-12-22 | 1994-03-08 | Suntory Limited | Compound effective as cerebral insufficiency improver |
US5179092A (en) | 1987-12-22 | 1993-01-12 | Suntory Limited | Compound effective as cerebral insufficiency improver |
DK36389A (da) | 1988-02-05 | 1989-08-06 | Eastman Kodak Co | Praeparat og fremgangsmaade til at forebygge vaevskader ved reperfusion |
JPH01209445A (ja) | 1988-02-17 | 1989-08-23 | Fuji Photo Film Co Ltd | 放射線感応性材料 |
JP2685785B2 (ja) | 1988-03-11 | 1997-12-03 | エーザイ株式会社 | 光学活性α−トコトリエノールの製造方法 |
JPH029875A (ja) | 1988-03-16 | 1990-01-12 | Bio Ind Kyokai | トコフェロール及びトコトリエノールの製造方法 |
DE3818696C1 (en) | 1988-06-01 | 1989-03-30 | Ems-Inventa Ag, Zuerich, Ch | Process for the preparation of hydroquinone and its alkyl derivatives |
US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
JPH08768B2 (ja) | 1989-08-24 | 1996-01-10 | 武田薬品工業株式会社 | 神経成長因子分泌誘導剤 |
FI102273B (fi) | 1989-09-11 | 1998-11-13 | Eisai Co Ltd | Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö |
FR2657345B1 (fr) | 1990-01-19 | 1992-05-07 | Rhone Poulenc Chimie | Procede de c-alkylation de l'hydroquinone et de ses monoethers. |
US5157132A (en) | 1990-05-18 | 1992-10-20 | Carotech Associates | Integrated process for recovery of carotenoids and tocotrienols from oil |
ATE132366T1 (de) | 1990-05-29 | 1996-01-15 | Boston Ocular Res | Zusammensetzung zur behandlung von dry eye erkrankungen |
ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
JP3086284B2 (ja) | 1991-07-05 | 2000-09-11 | 京セラミタ株式会社 | 電子写真感光体 |
ZA927277B (en) | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
EP0543417A1 (en) | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotrienols and tocotrienol-like compounds and methods for their use |
EP0560568A3 (en) | 1992-03-13 | 1994-06-29 | Takeda Chemical Industries Ltd | Hydroquinone derivatives and intermediates for production thereof |
US5981601A (en) | 1992-05-28 | 1999-11-09 | Centre For Molecular Biology And Medicine | Method for enhancing cellular bioenergy |
CN1093360A (zh) | 1992-10-02 | 1994-10-12 | 武田药品工业株式会社 | 2-o-烷基抗坏血酸的锂盐 |
US5318993A (en) * | 1993-04-16 | 1994-06-07 | Bristol-Myers Squibb Company | Antihyperlipidemic benzoquinones |
DE69420776T2 (de) | 1993-06-18 | 2000-05-18 | Takeda Chemical Industries Ltd | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer |
US5600029A (en) | 1994-03-09 | 1997-02-04 | Takeda Chemical Industries, Ltd. | Process for producing DL-tocopherols and intermediates therefor |
CN1129400A (zh) | 1994-05-06 | 1996-08-21 | 阿尔康实验室公司 | 维生素e生育酚衍生物在眼科组合物中的应用 |
US6133278A (en) | 1994-08-12 | 2000-10-17 | Takeda Chemical Industries, Ltd. | Use of quinone and hydroquinone derivatives for the treatment of cachexia |
US6150402A (en) | 1994-08-15 | 2000-11-21 | Loma Linda University Medical Center | Natriuretic compounds |
JPH0892151A (ja) | 1994-09-29 | 1996-04-09 | Sagami Chem Res Center | アリルキノンの製造方法 |
US5547827A (en) | 1994-12-22 | 1996-08-20 | Eastman Kodak Company | Iodochloride emulsions containing quinones having high sensitivity and low fog |
EP0719552A3 (en) | 1994-12-26 | 1997-08-20 | Takeda Chemical Industries Ltd | Pharmaceutical composition containing a quinone derivative or the hydroquinone thereof for the treatment of dermatitis |
KR100264348B1 (ko) | 1994-12-28 | 2000-08-16 | 디르크 반테 | 항-죽종형성제로서 네비볼롤을 함유하는 조성물 |
US5872108A (en) | 1995-03-06 | 1999-02-16 | Interneuron Pharmaceuticals, Inc. | Reduction of infarct volume using citicoline |
US20030134028A1 (en) | 1995-06-01 | 2003-07-17 | Lipton, Division Of Conopco, Inc. | Fat based food products |
EP0846109B1 (en) | 1995-08-21 | 2002-07-24 | Takeda Chemical Industries, Ltd. | Quinone compound, its production and use |
US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
PT842165E (pt) | 1996-03-25 | 2001-08-30 | Alcon Laboratoires Inc | Derivados de acido tiazolidina-4-carboxilico como agentes citoprotectores |
WO1998002149A2 (en) | 1996-07-11 | 1998-01-22 | Takeda Chemical Industries, Ltd. | Use of idebenone and analogues against beta amyloid induced cytotoxicity |
FR2753098B1 (fr) | 1996-09-06 | 1998-11-27 | Sod Conseils Rech Applic | Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene |
GB9702310D0 (en) | 1997-02-05 | 1997-03-26 | Univ Hertfordshire | Invention |
GB9722361D0 (en) | 1997-10-24 | 1997-12-17 | Pharma Nord Uk Ltd | Pharmaceutical formulation for treating liver disorders |
AU746369B2 (en) | 1997-11-17 | 2002-04-18 | Lipogenics, Inc. | Methods for preventing restenosis using tocotrienols |
US6331532B1 (en) | 1998-11-25 | 2001-12-18 | University Of Otago | Mitochondrially targeted antioxidants |
EP1051411B1 (en) | 1998-01-29 | 2002-08-28 | Eastman Chemical Company | Methods for separating a tocol from a tocol-containing mixture |
US5969133A (en) | 1998-05-22 | 1999-10-19 | Shiongi Bioresearch Corp. | Bioreductive cytotoxic agents |
US6433199B1 (en) | 1998-05-22 | 2002-08-13 | Shionogi Bioresearch Corporation | Quinone derivatives |
KR20010072080A (ko) | 1998-07-31 | 2001-07-31 | 쓰끼하시 다미까따 | 페닐아졸 화합물, 그의 제조 방법 및 고지혈증용 약제 |
US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
IT1304406B1 (it) | 1998-10-21 | 2001-03-19 | Danital Italia S R L | Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3. |
US6187811B1 (en) | 1998-10-28 | 2001-02-13 | Lipogenics, Inc. | Methods for treating benign prostatic hyperplasia using tocotrienols |
US6133322A (en) | 1998-10-29 | 2000-10-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Quinone derivatives for treating or preventing diseases associated with iron overload |
US6562372B1 (en) | 1998-11-06 | 2003-05-13 | Fuji Chemical Industry Co., Ltd. | Tocotrienol-containing powder, a process for preparing it and a tablet comprising compressed said powder into a tablet form |
US6048891A (en) | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
JP2000202297A (ja) | 1999-01-20 | 2000-07-25 | Chemiprokasei Kaisha Ltd | 新規な酸化反応用触媒およびそれを用いたp―ベンゾキノン類の製造方法 |
NZ513926A (en) | 1999-02-23 | 2001-09-28 | Univ California | Methods of treatment of mitochondrial disorders |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6303801B1 (en) | 1999-03-09 | 2001-10-16 | Sumitomo Chemical Company, Limited | Process for producing alkyl-substituted hydroquinones |
US6045826A (en) | 1999-04-02 | 2000-04-04 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
US6632443B2 (en) | 2000-02-23 | 2003-10-14 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
WO2000078296A2 (en) | 1999-06-17 | 2000-12-28 | Basf Aktiengesellschaft | Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders |
US6395915B1 (en) | 1999-09-10 | 2002-05-28 | Technikrom, Inc. | Method for producing purified tocotrienols and tocopherols using liquid chromatography |
US6426362B1 (en) | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
MY127451A (en) | 1999-11-04 | 2006-12-29 | Malaysian Palm Oil Board | A method of chromatographic isolation for vitamin e isomers |
US8753675B1 (en) | 2000-01-20 | 2014-06-17 | Raj K. Chopra | Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications |
US6740338B1 (en) | 2000-01-20 | 2004-05-25 | Raj K. Chopra | Reduced form of Cenzyme Q in high bioavailability stable oral dosage form |
US6346544B2 (en) | 2000-03-02 | 2002-02-12 | Oklahoma Medical Research Foundation | Desmethyl tocopherols for protecting cardiovascular tissue |
WO2001092215A2 (en) | 2000-06-02 | 2001-12-06 | Us Health | Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same |
DE10034233A1 (de) | 2000-07-14 | 2002-01-24 | Basf Ag | Tocotrienolchinon-Cyclisierungsprodukte |
US6545184B1 (en) | 2000-08-15 | 2003-04-08 | The Regents Of The University Of California | Practical, cost-effective synthesis of COQ10 |
US20030206972A1 (en) | 2000-10-13 | 2003-11-06 | Babish John G. | Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect |
WO2002034259A1 (en) | 2000-10-26 | 2002-05-02 | Fournier Laboratories Ireland Limited | Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
AUPR177300A0 (en) | 2000-11-29 | 2000-12-21 | Centre For Molecular Biology And Medicine | Therapeutic methods |
US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
WO2002047680A2 (en) | 2000-12-15 | 2002-06-20 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
US6838104B2 (en) | 2000-12-20 | 2005-01-04 | Archer Daniels Midland Company | Process for the production of tocotrienols |
US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
US6300377B1 (en) | 2001-02-22 | 2001-10-09 | Raj K. Chopra | Coenzyme Q products exhibiting high dissolution qualities |
US6764768B2 (en) | 2001-02-28 | 2004-07-20 | Arch Development Corporation | Controlled release composition |
JP2002298952A (ja) | 2001-03-29 | 2002-10-11 | Tyco Electronics Amp Kk | 電気コネクタ |
US6964969B2 (en) | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
JP2003064017A (ja) | 2001-06-12 | 2003-03-05 | Hokko Chem Ind Co Ltd | オキシスチレン誘導体の蒸留方法 |
US7172905B2 (en) | 2001-08-07 | 2007-02-06 | The University Of Chicago | Polypeptide immobilization |
NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
AU2002327517B2 (en) | 2001-08-21 | 2008-04-17 | Johnson & Johnson Consumer Companies, Inc. | Tocopherol enriched compositions and amelioration of inflammatory symptoms |
CA2357053A1 (en) | 2001-09-04 | 2003-03-04 | Unknown | Effectiveness of a combination of antioxidant substances for the treatment of alzheimer's disease |
JP2003137716A (ja) | 2001-10-30 | 2003-05-14 | Eau De Faveur:Kk | 皮膚の外用剤 |
AU2002352726A1 (en) | 2001-11-15 | 2003-06-10 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
US20040152764A1 (en) | 2001-12-14 | 2004-08-05 | Miller Guy M. | Compositions and methods for the prevention and treatment of cerebral ischemia |
US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
US7078541B2 (en) | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
GB0204232D0 (en) | 2002-02-22 | 2002-04-10 | Isis Innovation | Assay |
AT414082B (de) | 2002-05-03 | 2006-09-15 | Vis Vitalis Lizenz & Handels | Verfahren zur herstellung von tocotrienol-angereicherten präparationen |
ATE328283T1 (de) | 2002-07-01 | 2006-06-15 | Santhera Pharmaceuticals Ch | Screeningverfahren und verbindungen zur behandlung von friedreich ataxia |
US6953331B2 (en) | 2002-08-30 | 2005-10-11 | Extreme Components L.P. | Positioning device with bearing mechanism |
JP4599292B2 (ja) | 2002-10-30 | 2010-12-15 | エジソン ファーマシューティカルズ, インコーポレイテッド | 物理的−化学的特性に基づく治療用化合物の同定 |
US20070135335A1 (en) | 2003-02-10 | 2007-06-14 | Autogen Research Pty Ltd. | Therapeutic molecules |
RU2006101991A (ru) | 2003-06-25 | 2006-06-27 | Чарлз ЭРВИН (US) | Химическая композиция и способ увеличения подачи кофермента q10 |
KR20060113651A (ko) | 2003-08-08 | 2006-11-02 | 더 오하이오 스테이트 유니버시티 리서치 파운데이션 | 토코트리에놀의 보호 용도 및 치료 용도 |
BRPI0413742B8 (pt) | 2003-08-22 | 2021-05-25 | Antipodean Pharmaceuticals Inc | composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante |
US7015243B2 (en) | 2003-08-28 | 2006-03-21 | Allergan, Inc. | Cyclohexyl prostaglandin analogs as EP4-receptor agonists |
CA2580584C (en) | 2003-09-19 | 2015-07-28 | Galileo Pharmaceuticals, Inc. | Use of alpha-tocotrienol for treatment of mitochondrial diseases |
US20050074447A1 (en) | 2003-10-01 | 2005-04-07 | Papas Andreas M. | Treatment for diabetic microvascular and macrovascular complications |
WO2005035491A2 (en) | 2003-10-10 | 2005-04-21 | Yasoo Health, Inc. | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND |
US7118688B2 (en) | 2004-02-23 | 2006-10-10 | The Texas A&M University System | Antioxidant compositions and methods of use thereof |
US7022441B2 (en) | 2004-02-25 | 2006-04-04 | Eastman Kodak Company | Silver-free black-and-white thermographic materials containing a benzoquinone and methods of imaging |
WO2005084660A1 (ja) | 2004-03-05 | 2005-09-15 | Morishige, Fumie | ミトコンドリア病予防と対策 |
JP5129563B2 (ja) | 2004-03-18 | 2013-01-30 | ラスク・インテレクチュアル・リザーブ・アクチェンゲゼルシャフト | 視神経症に対する感受性を診断または予測するための方法 |
US7485283B2 (en) | 2004-04-28 | 2009-02-03 | Lantheus Medical Imaging | Contrast agents for myocardial perfusion imaging |
WO2005115478A2 (en) | 2004-05-11 | 2005-12-08 | The Regents Of The University Of California | Methods and compositions for autism spectrum disorders |
DE102004032837A1 (de) | 2004-07-02 | 2006-02-09 | Beiersdorf Ag | Verwendung von Wirkstoffkombinationen aus einem oder mehreren Biochinonen und einem oder mehreren Isoflavonen zur Verbesserung der Hautkonturen |
EP1611879B1 (en) | 2004-07-02 | 2009-08-12 | Novagali Pharma SA | Use of emulsions for intra- and periocular injection |
US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
KR101270841B1 (ko) | 2005-02-28 | 2013-06-05 | 가부시키가이샤 메이지 | 히드로퀴논 장쇄 유도체 및/또는 페녹시 장쇄 유도체 및 이들을 함유하는 의약 |
EP1885353B1 (en) | 2005-04-22 | 2015-01-07 | Elizabeth Stuart | Use of vitamin e tocotrienols for the inhibition of intracellularly obligate pathogen chlamydia |
ES2714900T3 (es) | 2005-06-01 | 2019-05-30 | Bioelectron Tech Corp | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
TW200744458A (en) | 2005-06-30 | 2007-12-16 | Kyowa Chem Ind Co Ltd | Antibacterial agent composed of silver-containing aluminum sulfate hydroxide particles and use thereof |
WO2007035496A1 (en) | 2005-09-15 | 2007-03-29 | Edison Pharmaceuticals, Inc. | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
EP1924292A2 (en) | 2005-09-16 | 2008-05-28 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
US20070248590A1 (en) | 2005-12-02 | 2007-10-25 | Sirtris Pharmaceuticals, Inc. | Modulators of CDC2-like kinases (CLKS) and methods of use thereof |
US20070208086A1 (en) | 2006-02-15 | 2007-09-06 | The Regents Of The University Of California | Ubiquinone analogs and methods of use |
JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
JPWO2007116750A1 (ja) | 2006-03-30 | 2009-08-20 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子用材料、及びこれを用いた有機エレクトロルミネッセンス素子 |
CN101610782A (zh) | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱 |
WO2008157747A1 (en) | 2007-06-21 | 2008-12-24 | The Jackson Laboratory | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders |
CN101827523A (zh) | 2007-08-16 | 2010-09-08 | 马库赛特公司 | 用于治疗眼部疾病或病症的制剂 |
US8075909B2 (en) | 2007-09-04 | 2011-12-13 | University Of Florida Research Foundation, Incorporated | Contact lens based bioactive agent delivery system |
EP3456707B1 (en) | 2007-11-06 | 2020-04-15 | PTC Therapeutics, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
CA2710253A1 (en) | 2008-01-07 | 2009-07-16 | Centocor Ortho Biotech Inc. | Method of treating erythropoietin hyporesponsive anemias |
US8952071B2 (en) | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
JP5710277B2 (ja) | 2008-03-05 | 2015-04-30 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス疾患の処置のための2−置換−p−キノン誘導体 |
US20110046156A1 (en) | 2008-03-05 | 2011-02-24 | Miller Guy M | Treatment of hearing and balance impairments with redox-active therapeutics |
CA2723621A1 (en) | 2008-05-15 | 2009-11-19 | Edison Pharmaceuticals, Inc | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
WO2009143268A2 (en) | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
US8716486B2 (en) | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
US20100010100A1 (en) | 2008-07-09 | 2010-01-14 | Hinman Andrew W | Dermatological compositions with anti-aging and skin even-toning properties |
WO2010014758A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress |
US20100029784A1 (en) | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
US8314153B2 (en) | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
JP5731980B2 (ja) | 2008-10-09 | 2015-06-10 | ラムズコア, インコーポレイテッド | ドライアイ症候群の処置のための組成物および方法 |
EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
DK2362875T3 (en) | 2008-10-28 | 2015-11-30 | Edison Pharmaceuticals Inc | METHOD OF PRODUCING ALPHA-tocotrienol AND DERIVATIVES |
WO2010126910A1 (en) | 2009-04-28 | 2010-11-04 | Edison Pharmaceuticals, Inc. | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
US20100273892A1 (en) | 2009-04-28 | 2010-10-28 | Miller Guy M | Formulations of tocotrienol quinones for the treatment of ophthalmic diseases |
HUE037574T2 (hu) | 2009-04-28 | 2018-09-28 | Bioelectron Tech Corp | Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal |
EP2609921A1 (en) | 2009-06-25 | 2013-07-03 | Ampere Life Sciences, Inc. | Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts |
CN102647981B (zh) | 2009-08-26 | 2016-09-28 | 爱迪生制药有限公司 | 预防和治疗脑缺血的方法 |
WO2011041452A2 (en) | 2009-10-01 | 2011-04-07 | Ampere Life Sciences, Inc. | Mouse model for identifying compounds for the treatment of oxidative stress |
US20110172312A1 (en) | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
EA201201374A1 (ru) | 2010-04-06 | 2013-04-30 | Эдисон Фармасьютикалз, Инк. | Лечение атаксии-телеангиэктазии |
MY183449A (en) | 2010-04-27 | 2021-02-18 | Bioelectron Tech Corp | Formulations of quinones for the treatment of ophthalmic diseases |
WO2012009271A1 (en) | 2010-07-14 | 2012-01-19 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
JP6045494B2 (ja) | 2010-08-06 | 2016-12-14 | エジソン ファーマシューティカルズ, インコーポレイテッド | ナフトキノンによるミトコンドリア病の処置 |
WO2012019032A1 (en) | 2010-08-06 | 2012-02-09 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
WO2012068552A1 (en) | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
US20150057363A1 (en) | 2011-07-06 | 2015-02-26 | Guy M. Miller | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
US9162957B2 (en) | 2011-07-19 | 2015-10-20 | Edison Pharmaceuticals, Inc. | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
US9629815B2 (en) | 2012-09-07 | 2017-04-25 | Bioelectron Technology Corporation | Benzoquinone derivatives for treating oxidative stress disorders |
EP2970158B1 (en) | 2013-03-15 | 2019-02-20 | BioElectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
EP3004071A1 (en) | 2013-05-31 | 2016-04-13 | Edison Pharmaceuticals, Inc. | Carboxylic acid derivatives for treatment of oxidative stress disorders |
RU2770091C2 (ru) | 2014-12-16 | 2022-04-14 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида |
JP2018500317A (ja) | 2014-12-16 | 2018-01-11 | バイオエレクトロン テクノロジー コーポレイション | トロロックスのキラル分割のための方法 |
US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
WO2018081644A1 (en) | 2016-10-28 | 2018-05-03 | Bioelectron Technology Corporation | Methods of analyzing p-hydroquinone levels and ratios |
WO2018093957A1 (en) | 2016-11-15 | 2018-05-24 | Bioelectron Technology Corporation | 2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof cross reference to related applications |
-
2006
- 2006-06-01 ES ES12195108T patent/ES2714900T3/es active Active
- 2006-06-01 PL PL06784530T patent/PL1888059T3/pl unknown
- 2006-06-01 EP EP06784530.5A patent/EP1888059B1/en active Active
- 2006-06-01 CA CA2996149A patent/CA2996149A1/en not_active Abandoned
- 2006-06-01 PT PT67845305T patent/PT1888059E/pt unknown
- 2006-06-01 PL PL12195108T patent/PL2564843T3/pl unknown
- 2006-06-01 DK DK06784530.5T patent/DK1888059T3/en active
- 2006-06-01 SI SI200631901T patent/SI1888059T1/sl unknown
- 2006-06-01 EP EP12195101A patent/EP2564842A1/en not_active Withdrawn
- 2006-06-01 CA CA2610152A patent/CA2610152C/en active Active
- 2006-06-01 WO PCT/US2006/021295 patent/WO2006130775A2/en active Application Filing
- 2006-06-01 HU HUE12162555A patent/HUE033304T2/en unknown
- 2006-06-01 DK DK12162555.2T patent/DK2471530T3/en active
- 2006-06-01 EP EP12162555.2A patent/EP2471530B1/en active Active
- 2006-06-01 MX MX2012009599A patent/MX359292B/es unknown
- 2006-06-01 EA EA201101668A patent/EA035619B1/ru not_active IP Right Cessation
- 2006-06-01 ES ES06784530.5T patent/ES2532912T3/es active Active
- 2006-06-01 JP JP2008514860A patent/JP2008542389A/ja not_active Withdrawn
- 2006-06-01 DK DK12195108.1T patent/DK2564843T3/en active
- 2006-06-01 MX MX2007015006A patent/MX2007015006A/es active IP Right Grant
- 2006-06-01 PT PT121625552T patent/PT2471530T/pt unknown
- 2006-06-01 ES ES12162555.2T patent/ES2619303T3/es active Active
- 2006-06-01 EA EA200702622A patent/EA016226B1/ru not_active IP Right Cessation
- 2006-06-01 US US11/445,582 patent/US9447006B2/en active Active
- 2006-06-01 EP EP12195108.1A patent/EP2564843B1/en active Active
- 2006-06-01 PL PL12162555T patent/PL2471530T3/pl unknown
-
2008
- 2008-03-11 HK HK08102837.5A patent/HK1108651A1/xx not_active IP Right Cessation
-
2010
- 2010-05-10 US US12/777,179 patent/US11021424B2/en active Active
- 2010-10-19 MX MX2010011492A patent/MX2010011492A/es active IP Right Grant
-
2012
- 2012-09-21 JP JP2012207828A patent/JP2012250997A/ja active Pending
-
2013
- 2013-02-20 JP JP2013030630A patent/JP5631428B2/ja active Active
-
2014
- 2014-06-20 JP JP2014126926A patent/JP2014169334A/ja not_active Withdrawn
-
2015
- 2015-11-25 JP JP2015229350A patent/JP2016029112A/ja not_active Withdrawn
-
2017
- 2017-10-05 JP JP2017195027A patent/JP2018002736A/ja not_active Withdrawn
-
2021
- 2021-05-28 US US17/334,601 patent/US20220055975A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201101668A1 (ru) | Редокс-активные терапевтические средства для лечения митохондриальных нарушений | |
CY1123740T1 (el) | Παραλλαγες ακρων δραστικων οξειοδοαναγωγικων θεραπειων για αγωγη σε μιτοχονδριακες νοσους και αλλες καταστασεις και ρυθμιση των ενεργειακων βιοδεικτων | |
EA201001119A1 (ru) | Производные (гет)арил-п-хинона для лечения митохондриальных болезней | |
EA200801623A1 (ru) | Варианты редокс-активных терапевтических средств для лечения митохондриальных заболеваний и других состояний и модуляции биомаркеров энергии, отличающиеся по боковой цепи | |
CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
EP2601168A4 (en) | TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K | |
MX338572B (es) | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales. | |
MX2013001469A (es) | Tratamiento de enfermedades mitocondriales con naftoquinonas | |
CR7785A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
BR112015023753A2 (pt) | composições, formulações e métodos para o tratamento de doenças oculares | |
PA8548401A1 (es) | Agentes antibacterianos | |
PT1140139E (pt) | Utilizacao de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral | |
DE60331537D1 (de) | Kombinationen zur behandlung von multiplem myelom | |
CR20160269A (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento del cancer y enfermedades comunes | |
BR112018008601A2 (pt) | composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer | |
MX2021010888A (es) | Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis. | |
CY1124907T1 (el) | Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
CO2017006983A2 (es) | Una composición fungicida que comprende una n-ciclopropil- n-[bencilo sustituido]-3-(difluorometil)-5-fluoro-1- metil-1-h-pirazol-4-carboxamida o derivado de tiocarboxamida y dos compuestos fungicidas activos adicionales | |
PA8607201A1 (es) | Derivados sustituidos del dioxido de tiazol-benzoisotiazol, procedimiento para su preparacion y su uso | |
CR20220199A (es) | Inhibidores del factor d del complemento para administración oral | |
BRPI0414334A (pt) | withanamida isolada e purificada, composto isolado e purificado, método para tratamento de uma doença in vivo em um mamìfero, método para provisão de oxidação em uma composição necessitada da mesma, composição, composição para uso como produto farmacêutico, método para tratamento de uma doença selecionada do grupo que conpreende a doença de alzheimer, obesidade, dores de cabeça de enxaqueca, e depressão, em um paciente, e método para tratamento antioxidante de um mamìfero in vivo | |
IT201700047189A1 (it) | Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie | |
BR112022011344A2 (pt) | Compostos para tratamento de doença de alzheimer e uso desses compostos | |
CL2023000800A1 (es) | Compuestos de cromanol para el tratamiento de la insuficiencia cardíaca | |
GEP20237472B (en) | Oral care product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG MD TJ TM |